バイオテクノロジー　欧州企業ポスター展示 in BioJapan2019

3P Biopharmaceuticals (3P) is a leading European CDMO specialized in the process development and GMP manufacturing of biologics products using microbial and mammalian expression systems.

3P offers solutions for biologics at all stages of product development: from research and development, all through the preclinical and clinical phases to commercial supply.

During more than 12 years 3P has worked with more than 50 different recombinant proteins and other biologics. It can support biologics with process and analytics development, Drug substance (DS) and Drug Product (DP) testing, release and stability, as well as GMP material supply for clinical trials and market.

Applied Research using Omic Sciences (AROMICS) is a development stage biotech company founded in 2005, with facility at the Science Park of Barcelona, focused on the development of novel therapies for the treatment of cancer.

We are currently developing a family of Novel Chemical Entities protected under granted patents with a pioneering mechanism of action: binding RNA and silencing aberrant proteins overexpressed in cancer. First lead advancing to clinics is a first-in-class antitumor agents acting in a well-characterized pathway and devoted to treat malignant mesothelioma, a rare and aggressive cancer linked to asbestos exposure.

Our key clients are large pharmaceutical and biotech companies working in oncology area. We are looking for co-development agreements and additional funding for advance in the clinical development up to first-in-man (efficacy Phase II clinical studies). Additionally, we aim to expand the cooperation agreement with groups actively working on the mesothelioma field, in order to explore possibilities of partnership and research cooperation that sharing risk and reward based on the work and resources that are needed to create value in the compounds.

フランス

Da Volterra is a Paris-based clinical stage biotech company developing unique and novel Microbiota Protective Therapies that address large unmet medical needs in the oncology and infectious diseases' spaces.

Da Volterra's lead product is DAV132, a Microbiota Protective Therapy that quenches the effects of antibiotics on the intestinal microbiota in order to:

i.　  Potentiate the efficacy of immune checkpoint inhibitors when patients take antibiotics, as it was recently shown in 28 studies that the microbiota state can greatly influence the efficacy of immuno-oncology drugs and significantly decrease patients' survival;

ii.　Prevent Clostridioides difficile infections in patients at risk.

DAV132 could change the practice of antibiotic therapies and has already demonstrated strong clinical evidence of intestinal microbiota protection from antibiotic-induced dysbiosis. DAV132 has been successfully given to 235 healthy volunteers with no adverse events or safety concerns. DAV132 is currently evaluated as part of a Phase 2 clinical trial whose top-line results are anticipated for Q1 2020.

Da Volterra is actively looking to explore out-licensing or co-development business opportunities with pharma / biotech / health companies and investors.

ISA Pharmaceuticals is a clinical stage biotech company focused on the development therapeutics vaccines, based on our synthetic long peptide (SLP®) technology. Our lead product ISA101b that targets HPV16 positive cancers, is entering phase 3 in a partnership with Regeneron.

Next in our pipeline are three products ready for clinical testing: ISA102 that targets cancers caused by HPV types other than HPV16, ISA103 for cancers that (over-)express cancer testis antigen PRAME, and ISA104 to potentially cure chronic HBV. We are looking for partners to further (clinically) develop these assets for the Japanese, Asian or global markets.

GenomeUp is a precision medicine solution focused on enabling physicisians and clinical institutions to accurately and timely diagnose and treat patients affected from rare genetic diseases.

By leveraging proprietary algorithms and A.I., GenomeUp analyzes the patient's DNA, symptoms and drugs treatment to identify specific genes or sequences related to a specific disease and provides a complete, and holistic, clinical report based in the interpretation of million of scientific papers published in world public databases.

GenomeUp is enabling a precision medicine solution to streamlining the diagnose journey for physicians. We are a SaMD (Software as Medical Device) and our customers are hospitals and laboratories.

フィンランド

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.　We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

Selvita has expertise in providing integrated drug discovery support, starting from hit identification, H2L and lead optimization, combined with ADMET/DMPK and in vitro biochemical as well as functional assays for pharmacodynamic model development, validation and assessment of a drug efficacy.

Our support covers several areas:

- Medicinal & Synthetic chemistry - design of novel chemotypes and synthesis of innovative compounds and small libraries for screening purposes

- Computer Assisted Drug Discovery using AI and various Computational chemistry methods

- Structural Biology (Gene-to-Structure) - Production of custom recombinant proteins, protein crystallization

- ADME support

- PK in vivo studies

ViruSure is a privately-owned biotech company specializing in the virus and prion safety testing of biopharmaceutical products (Virus and Prion Clearance Studies, QC Testing, Virus Safety Risk Assessments), GMP Cell and Virus Banking and a host of other Biosafety Testing Services. We offer a wealth and breadth of expertise to ensure you meet all relevant Biosafety Testing requirements, all performed to exacting GLP/GMP standards.

Each biopharmaceutical product is unique and presents its own challenges with regards to potential viruses that might be present as contaminants. Our goal is to offer the highest level of quality, customer service and regulatory compliance for your pathogen safety testing and ensure that the strategy we develop with you will provide a high chance of success in satisfying all regulatory requirements at the first attempt Worldwide.